×
Back to Agenda
LS50: Transformation and Innovation in Drug Development with Environmental Changes Induced by COVID-19
Session Chair(s)
Marie Shiga
Manager, Health Industries Advisory, PwC Consulting LLC, Japan
- Introduction of the session - Transformation and innovation in drug development with environmental changes induced by COVID-19
Speaker(s)
Michiyo Ohshima, MBA
Senior Director, Head of Japan Portfolio and Project Management, Pfizer R&D GK, Japan
Noboru Yamamoto, MD, PHD
Deputy Director, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan
Minori Niso
Senior Director, Japan Strategy & Marketing, Parexel, Japan
Have an account?